P. Godwin

P. Godwin

Auto-generated profile, based on publicly available information

P. Godwin

Department of Clinical Medicine, Thoracic Oncology Research Group, Trinity College Dublin, St. James’s Hospital Ireland Dublin, Ireland

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2013 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
PGP. Godwin
P. Godwin
ABAnne-Marie Baird
Anne-Marie Baird
SHSusan Heavey
Susan Heavey
MBMartin Barr
Martin Barr
KOK. J. O’bYrne
K. J. O’bYrne
Kathy GatelyKathy Gately
Kathy Gately
Intrinsic or acquired resistance to chemotherapeutic agents is a common phenomenon and a major challenge in the treatment of cancer patients. Chemoresistance is defined by a complex network of factors including multi-drug resistance proteins, reduced cellular uptake of the drug, enhanced DNA repair, intracellular drug inactivation, and evasion of apoptosis. Pre-clinical models have demonstrated that many chemotherapy drugs, such as platinum-based agents, antracyclines, and taxanes, promote the activation of the NF-κB pathway. NF-κB is a key transcription factor, playing a role in the development and progression of cancer and chemoresistance through the activation of a multitude of mediators including anti-apoptotic genes. Consequently, NF-κB has emerged as a promising anti-cancer target. Here, we describe the role of NF-κB in cancer and in the development of resistance, particularly cisplatin. Additionally, the potential benefits and disadvantages of targeting NF-κB signaling by pharmacological intervention will be addressed.